General Information of the Compound
Compound ID
CP0077074
Compound Name
(2S)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one
    Show/Hide
Synonyms
(2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One
(S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one
1032754-93-0
1C854K1MIJ
Apitolisib
Apitolisib (GDC-0980, RG7422)
C23H30N8O3S
CHEMBL1922094
GDC-0980
GDC-0980 (RG7422)
GDC-0980/RG7422
GDC0980
J-502360
RG-7422
RG7422
UNII-1C854K1MIJ
    Show/Hide
Structure
Formula
C23H30N8O3S
Molecular Weight
498.613
Canonical SMILES
C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1
    Show/Hide
InChI
InChI=1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,15,32H,3-10,13H2,1-2H3,(H2,24,25,26)/t15-/m0/s1
    Show/Hide
InChIKey
YOVVNQKCSKSHKT-HNNXBMFYSA-N
CAS
1032754-93-0
Physicochemical Property
logP
0.90052
Rotatable Bonds
5
Heavy Atom Count
35
Polar Areas
133.83
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
11
Complexity
35

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 25254071
SID: 58088126
ChEMBL ID
CHEMBL1922094
DrugBank ID
DB12180
Table of Molecular Bioactivities Related to the Compound
Cell Viability or Cytotoxicity Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000048 PC-3 Homo sapiens (Human)  1
1
IC50 = 307 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( GDC-0980/RG7422 )
Drug Name GDC-0980/RG7422
Company Genentech; Roche
Indication
Non-hodgkin lymphoma
Phase 2
Non-hodgkin lymphoma
Phase 1
Solid tumour/cancer
Phase 1
Target(s)
PI3-kinase gamma (PIK3CG)
Modulator
Serine/threonine-protein kinase mTOR (mTOR)
Modulator